Seroprevalence and determinants of eight high-risk human papillomavirus types in homosexual men, heterosexual men, and women: A population-based study in Amsterdam

Sexually Transmitted Diseases

Volumn 37, Issue 11, 2010, Pages 672-680

  Heiligenberg, Marlies ^a,b   Michael, Kristina M ^c   Kramer, Merlijn A ^d   Pawlita, Michael ^c   Prins, Maria ^a,b   Coutinho, Roel A ^a,d   Dukers Muijrers, Nicole H T M ^a,e   Waterboer, Tim ^c  

^a DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^b Center for Infection and Immunity Amsterdam CINIMA   (Netherlands)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^e South Limburg Public Health Service   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN L1; HYBRID PROTEIN; VIRUS ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIBODY SCREENING; ARTICLE; BLOOD SAMPLING; ETHNICITY; FEMALE; HERPES SIMPLEX VIRUS 2; HETEROSEXUALITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; INFECTION RISK; MALE; MALE HOMOSEXUAL; MULTIVARIATE ANALYSIS; NETHERLANDS; POISSON DISTRIBUTION; POPULATION RESEARCH; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; VIRUS CAPSID;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; HETEROSEXUALITY; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POPULATION SURVEILLANCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; YOUNG ADULT;

EID: 78149281564     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e3181e71069     Document Type: Article

References (44)

1. Bosch FX, Manos MM, Munoz N, et al; International biological study on cervical cancer (IBSCC) Study Group. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. J Natl Cancer Inst 1995;87:796-802.
2. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-527. (Pubitemid 36159887)
3. Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-1371.
4. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007;121:621-632.
5. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998;338:423-428.
6. af Geijersstam V, Kibur M, Wang Z, et al. Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 1998;177:1710-1714.
7. Shah KV, Viscidi RP, Alberg AJ, et al. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 1997;6:233-237.
8. Castle PE, Shields T, Kirnbauer R, et al. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis 2002;29:182-187.
9. Slavinsky J III, Kissinger P, Burger L, et al. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS 2001;12:516-523.
10. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002;186:1396-1402.
11. Svare EI, Kjaer SK, Nonnenmacher B, et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis 1997;176:876-883.
12. Viscidi RP, Kotloff KL, Clayman B, et al. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 1997;4:122-126.
13. Kirnbauer R, Hubbert NL, Wheeler CM, et al. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 1994;86:494-499.
14. Sehr P, Muller M, Hopfl R, et al. HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods 2002;106:61-70.
15. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005;51:1845-1853.
16. Clifford GM, Shin HR, Oh JK, et al. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 2007;16:1874-1879.
17. Syrjanen S, Waterboer T, Sarkola M, et al. Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol 2009;90:1515-1526.
18. Dondog B, Clifford GM, Vaccarella S, et al. Human papillomavirus infection in Ulaanbaatar, Mongolia: A population-based study. Cancer Epidemiol Biomarkers Prev 2008;17:1731-1738.
19. Michael KM, Waterboer T, Sehr P, et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog 2008;4: e1000091.
20. Karagas MR, Nelson HH, Sehr P, et al. Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin. J Natl Cancer Inst 2006;98:389-395.
21. Andersson K, Waterboer T, Kirnbauer R, et al. Seroreactivity to cutaneous human papillomaviruses among patients with nonmelanoma skin cancer or benign skin lesions. Cancer Epidemiol Biomarkers Prev 2008;17:189-195.
22. Rizk RZ, Christensen ND, Michael KM, et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 2008;89:117-129.
23. Kreimer AR, Alberg AJ, Viscidi R, et al. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16,-18, and-33 seroprevalence. Sex Transm Dis 2004;31:247-256.
24. Shin HR, Franceschi S, Vaccarella S, et al. Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis 2004;190:468-476.
25. Thompson DL, Douglas JM Jr, Foster M, et al. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 2004;190:1563-1574.
26. Wang SS, Schiffman M, Herrero R, et al. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10, 000 women in Costa Rica. Br J Cancer 2004;91:1269-1274.
27. Markowitz LE, Sternberg M, Dunne EF, et al. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009;200:1059-1067.
28. Newall AT, Brotherton JM, Quinn HE, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008;46:1647-1655.
29. Sehr P, Zumbach K, Pawlita M. A generic capture ELISA for recombinant proteins fused to glutathione S-transferase: Validation for HPV serology. J Immunol Methods 2001;253:153-162.
30. Zocchetti C, Consonni D, Bertazzi PA. Relationship between prevalence rate ratios and odds ratios in cross-sectional studies. Int J Epidemiol 1997;26:220-223.
31. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702-706.
32. van der Aa MA, Siesling S, Louwman MW, et al. Geographical relationships between sociodemographic factors and incidence of cervical cancer in the Netherlands 1989-2003. Eur J Cancer Prev 2008;17:453-459.
33. Visser O, Busquet EH, van Leeuwen FE, et al. Incidence of cervical cancer in women in North-Holland by country of birth from 1988-1998 [in Dutch]. Ned Tijdschr Geneeskd 2003;147:70-74.
34. Visser O, van Leeuwen FE. Cancer risk in first generation migrants in North-Holland/Flevoland, The Netherlands, 1995-2004. Eur J Cancer 2007;43:901-908.
35. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: A pooled analysis. Lancet 2005;366:991-998.
36. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 2007;7:453-459.
37. Tornesello ML, Duraturo ML, Buonaguro L, et al. Prevalence of human papillomavirus genotypes and their variants in high risk West Africa women immigrants in South Italy. Infect Agent Cancer 2007;2:1.
38. Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998;12:495-503.
39. Dunne EF, Nielson CM, Hagensee ME, et al. HPV 6/11, 16, 18 seroprevalence in men in two US cities. Sex Transm Dis 2009;36:671-674.
40. Partridge JM, Hughes JP, Feng Q, et al. Genital human papillomavirus infection in men: Incidence and risk factors in a cohort of university students. J Infect Dis 2007;196:1128-1136.
41. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996;174:927-936.
42. Wideroff L, Schiffman MH, Nonnenmacher B, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995;172:1425-1430.
43. van Loon AJ, Tijhuis M, Picavet HS, et al. Survey non-response in the Netherlands: Effects on prevalence estimates and associations. Ann Epidemiol 2003;13:105-110.
44. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000;181:1911-1919.